NINJA JOINS LA ROCHE-POSAY AS NEW PARTNER IN CAUSE FOR SKIN CANCER DETECTION AND PREVENTION
NEW YORK, March 21, 2025 /PRNewswire/ -- La Roche-Posay is proud to announce Tyler "NINJA" Blevins, world renown gamer, streamer, and entertainer, as its new partner in cause for the Save your Skin brand platform, dedicated to skin cancer prevention and detection.
This unprecedented collaboration comes a year after the 33 years old global icon shared with the world his melanoma diagnosis which was revealed during his annual mole check with a dermatologist.
"By sharing my personal experience far beyond my community, through the campaign with La Roche-Posay, I want to deliver a crucial message about skin cancer prevention: don't play games with detection," said Tyler "NINJA" Blevins, pro-gamer and melanoma survivor.
With an engaged and passionate fanbase across multiple digital platforms, NINJA has transcended the gaming industry, bringing an inclusive and powerful message that resonates with audiences globally.
Tyler "NINJA" Blevins embodies La Roche-Posay's core values of authenticity and transparency, anchoring this cause across multiple generations.
"Together, NINJA and La Roche-Posay are ushering in a new era of skin cancer awareness. With cases rising at an alarming rate,our mission is clear: to educate people about the importance of annual mole checks so that melanoma remains 99% preventable and treatable, especially among younger generations," said Alexandra Reni-Catherine, Global Brand General Manager for La Roche-Posay.
SAVE YOUR SKIN PROGRAMTo ensure a healthier future for all, La Roche-Posay has committed more than 20 years of research and awareness driving campaigns on the prevention and detection of skin cancer. With global initiatives in place to offer annual free mole checks in various communities and education campaigns with Dermatologists on sun safety habits, and self-detection via the ABCDE method. La Roche-Posay remains at the forefront of skin cancer awareness.
40%1 is the projected increase in melanoma rates for today's children by 2040.
99%2 of melanomas are curable if detected early.
70%3 of the population doesn't understand the difference between UVA which penetrates deep and causes aging and UVB which affects the surface and causes sunburn.
80%4 of the total lifetime UV exposure is received before the age of 18.
12%5 only of the global population systematically uses all protective measures during exposure.
200K free mole checks were offered by La Roche-Posay in 2024.
The Save your Skin campaign with NINJA will be launched during the EADV Congress in September 2025 in Paris.
For additional information about La Roche-Posay, visit www.laroche-posay.com and follow La Roche-Posay on Instagram, Tiktok, YouTube and Facebook.
ABOUT LA ROCHE-POSAYIn 2025, La Roche-Posay celebrates 50 years of life-changing dermatological skincare solutions. Created by a pharmacist in 1975, the brand is now present in over 60 countries and is recommended by 100,000 dermatologists worldwide. It provides a unique range of daily skincare developed for every skin type, from newborns to cancer patients, from UV protection to repairing severely fragilized skin.
1 Arnold et al. JAMA Dermatol. 2022;158(5)2 www.skincancer.org3 Passeron. J Eur Acad Dermatol Venereol. 2023;374 Raymond-Lezman JR, Riskin S. Attitudes, Behaviors, and Risks of Sun Protection. Cureus. 2023;15(2):e34934.5 Passeron. J Eur Acad Dermatol Venereol. 2023;37
View original content to download multimedia:https://www.prnewswire.com/news-releases/ninja-joins-la-roche-posay-as-new-partner-in-cause-for-skin-cancer-detection-and-prevention-302408336.html
SOURCE La Roche-Posay
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Rocketseed launches essential email signature guide for healthcare organizations
New resource helps healthcare providers improve branded communication, ensure HIPAA compliance, and boost patient engagement through smart email signature management. CHARLOTTE, N.C., June 6, 2025 /PRNewswire/ -- Rocketseed, a global leader in business email signature management and marketing, has released a new comprehensive resource, Healthcare Email Signature Management: An Essential Guide. Specifically developed for hospitals, clinics, and other healthcare providers, the guide shows how professionally managed email signatures can support compliance, strengthen branding, and enhance communication across the sector, increasing engagement amongst both patients and staff. With healthcare professionals under increasing pressure to meet data protection regulations like HIPAA, maintain patient trust, promote new treatments and key services, and strengthen workplace inclusivity, this guide offers practical, actionable advice for IT leaders, marketers, and frontline staff alike to achieve these goals - all through everyday email. Helping Healthcare Providers Stay Professional, Compliant and ConnectedThe guide outlines how to design, manage and run marketing campaigns with email signatures and banners to meet specific healthcare industry challenges and maximize results. Key topics include: Best practice email signature design tips and examples for healthcare professionals, including doctors and administrators. Benefits of centralized signature management, including guaranteed brand consistency, and saving IT time through automating all staff signature updates. Importance of using HIPAA (plus ISO27001, GDPR and POPIA) compliant email signature management software to ensure patient confidentiality and data protection. Use of targeted, interactive email banners for promoting seasonal health campaigns, patient education, and new treatments and services - all illustrated with examples. Internal email banner use for HR, training, and strengthening workplace culture. Role of robust analytics and real-time reporting in measuring email signature and banner success and ROI. Rocketseed's platform is HIPAA compliant, works across all email clients (including Microsoft 365 and Google Workspace) and devices, and helps healthcare IT teams save hundreds of hours through automation and user directory synchronization. "In today's highly-regulated healthcare environment, clear and compliant communication is essential," says Damian Hamp-Adams, North America CEO at Rocketseed. "Our guide shows how email signatures - when centrally managed and professionally designed - can do more than meet HIPAA requirements. They become a trusted communication tool across the entire organization." Driving Engagement Through Data and DesignThe guide also explores how analytics and real-time reporting can optimize engagement. Healthcare organizations can track all recipient interactions with their email banners and signature content, enabling smarter campaign decisions, such as refining designs and optimizing targeting, to generate greater return on their communication efforts. "Our goal is to help healthcare providers meet compliance needs while turning every email into a powerful communication channel," adds Damian. "This guide shows that with the right tools, even email signatures can play a vital role in delivering better patient care and stronger internal communication." This new release joins Rocketseed's growing library of industry-focused resources, including essential guides for hotels & hospitality, transportation & logistics, insurance, pharmaceutical and construction industries - each tailored to the unique compliance, branding, and communication needs of their sectors. About Rocketseed Rocketseed is a leading provider of email signature management and marketing solutions, used and trusted by businesses worldwide. With tools for centralized signature control, automated updates, targeted banner campaigns, and robust analytics, Rocketseed helps organizations maintain brand consistency, drive engagement, and ensure compliance — all through their everyday email. Learn more at Jennifer 547354 View original content to download multimedia: SOURCE Rocketseed (United States) Inc
Yahoo
4 hours ago
- Yahoo
Healthcare Simulation Market worth US$7.23 billion by 2030 with 15.6% CAGR
DELRAY BEACH, Fla., June 6, 2025 /PRNewswire/ -- The global Healthcare Simulation Market, valued at US$3.00 billion in 2024 stood at US$3.50 billion in 2025 and is projected to advance at a resilient CAGR of 15.6% from 2025 to 2030, culminating in a forecasted valuation of US$7.23 billion by the end of the period. This growth is likely to be driven by rising demand for standardized clinical training, increasing prevalence of chronic diseases, higher investment in healthcare technology, and more medical and nursing schools adopting simulation. Key contributors include patient simulators, interventional and cardiac surgical simulators, and simulation training services. Adoption is growing in hospitals and academic institutions, especially in North America and Asia Pacific. Governments are also supporting simulation-based training. For example, the University of Iowa received a USD 8-million grant from the Helmsley Charitable Trust to launch SIM-IA, a mobile simulation program for rural healthcare providers and first responders. Download PDF Brochure: Browse in-depth TOC on "Healthcare Simulation Market" 150 - Tables50 - Figures359 - Pages By Based on product & service, the healthcare simulation market, by product & service, is segmented into healthcare simulation anatomical models, healthcare simulation software, web-based simulation, and simulation training services. In 2024, the anatomical models accounted for the largest market share, driven by the increasing emphasis on patient safety and hands-on clinical training. These models allow medical students and professionals to practice procedures in a realistic, risk-free environment, enhancing clinical skills and reducing medical errors. As healthcare systems aim to improve efficiency and reduce costs, anatomical models are widely adopted as cost-effective alternatives to traditional training with live patients. Furthermore, the rising demand for minimally invasive procedures, ongoing advancements in surgical techniques, and growing funding for simulation-based education continue to boost their adoption in academic institutions and healthcare facilities, solidifying their position as the leading segment in the market. By Based on technology, the healthcare simulation market is segmented by technology into virtual patient simulation, 3D printing, and procedural rehearsal technology. Among these, the virtual patient simulation segment is expected to register the fastest growth rate during the forecast period due to its ability to provide immersive, risk-free, and repeatable training experiences for healthcare professionals. Leveraging virtual reality (VR) and augmented reality (AR) enables learners to practice clinical scenarios, decision-making, and patient interactions in highly realistic environments. This technology is particularly valuable for training in complex or rare medical cases that are difficult to encounter in real life. Several recent developments underscore this trend. For instance, in November 2024, VRAD Co., Ltd. launched NS_Core and IP_Trauma—two VR-based simulators for nursing and trauma care. Moreover, in July 2024, MediSim VR and KD Hospital opened India's first VR nurse training lab to enhance clinical skills through immersive simulation. These developments highlight the growing strategic focus on virtual patient simulation as a transformative tool in modern medical education and clinical training. By geography, in 2024, North America led the healthcare simulation market, mainly driven by sustained investments in mobile simulation technology and rural healthcare training. Notable initiatives include Washington State University's Mobile Simulation Program, launched in June 2024; the Simulation in Motion–Iowa (SIM-IA) program, launched in June 2022; and the Parkview Health Mobile Medical Training Lab (Indiana, USA), launched in May 2024. These programs are specifically designed to address the needs of underserved and rural communities, delivering high-fidelity simulation training directly to local healthcare providers. Such initiatives exemplify North America's commitment to expanding equitable access to simulation-based education. Furthermore, strong collaborations between academic institutions and healthcare systems, robust government support through initiatives such as the Health Resources and Services Administration (HRSA) grants, federal and state funding for mobile simulation units, and significant philanthropic funding have positioned North America as a global leader in healthcare simulation. These combined efforts enhance clinical preparedness, improve healthcare delivery, and ultimately strengthen patient outcomes across the region. Request Sample Pages : The key players functioning in the healthcare simulation market include CAE Inc. (Canada), Laerdal Medical (Norway), Gaumard Scientific Co. (US), Kyoto Kagaku (Japan), Limbs & Things (UK), Mentice AB (Sweden), Simulab Corporation (US), Simulaids (US), Intelligent Ultrasound Group PLC (UK), and Operative Experience Inc. (UK), and Surgical Science Sweden AB (Sweden), among others. CAE Inc. (Canada): CAE Inc. is a leader in simulation and training technologies, with a specialized Healthcare division offering high-fidelity patient simulators, ultrasound simulators, pediatric simulators, and surgical simulation systems. The company operates globally across 80+ countries, leveraging direct and partner-driven channels. CAE's core competencies include AR/VR integration, haptic feedback, and simulation center management. Major activities include strategic partnerships, acquisitions (e.g., Medicor), and R&D investments. CAE focuses on developing innovative training solutions, such as Vimedix and LucinaAR, and supports simulation research through collaborations with global universities, enhancing clinical skills and patient outcomes. Laerdal Medical (Norway) Laerdal Medical specializes in simulation-based training to improve patient outcomes, offering high-fidelity patient simulators, CPR manikins, and task trainers. The company's core competencies lie in scalable digital learning, resuscitation, and trauma care training. Major activities include acquisitions (e.g., B-Line Medical) and partnerships (e.g., SimX for VR simulation). Laerdal strongly focuses on innovation and adaptive learning, collaborating with global organizations such as the American Heart Association and GAVI. These initiatives enable Laerdal to lead in digital healthcare education and significantly advance clinical competency and patient safety. For more information, Inquire Now! Related Reports: Healthcare Education Market Healthcare Analytical Testing Services Market Healthcare IT Market Healthcare Analytics Market Remote Patient Monitoring Market Get access to the latest updates on Healthcare Simulation Companies and Healthcare Simulation Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
Key presentations include two updates from a phase 3 trial evaluating investigational treatment with Mim8 (denecimig) and five assessing treatment outcomes with concizumab in hemophilia A phase 3 trial analysis from FRONTIER5 will evaluate the safety of switching directly from emicizumab to Mim8 (denecimig) in people living with hemophilia A/B Findings from explorer7 and explorer8 phase 3 trials will assess data including non-joint bleeds, annualized bleeding rates and additional studies including thrombin generation with concizumab in hemophilia A/B PLAINSBORO, N.J., June 6, 2025 /PRNewswire/ -- Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25. Key data presentations across both hemophilia A and B (HA and HB), with and without inhibitors, will share insights on clotting, thrombin generation, bleeding episodes and medication impact, patient administration preferences, physician treatment satisfaction, and global real-world diagnosis and treatment data for joint bleeds. "At Novo Nordisk, we believe understanding the whole person and their journey is essential to addressing the unmet needs in people with hemophilia. Our research is rooted in a deep understanding of the hemophilia community, aiming to drive critical advancements across rare blood disorders in order to help address these unmet needs," said Stephanie Seremetis, Chief Medical Officer and CVP for Rare Disease at Novo Nordisk. "Through this latest research, we are honored to build on our long-standing legacy in rare blood disorders to support patients who face the challenges of this complex condition." New phase 3 data will be presented on Mim8, an investigational mimetic therapy designed to replicate the function of missing clotting factors.1 Analysis from the phase 3 FRONTIER5 trial will assess the safety and preferences of people with HA, with and without inhibitors, who switch from emicizumab to Mim8. In addition, new data from two prospective, multicenter, open label, phase 3 trials (explorer7 and explorer8) will investigate joint bleeds, non-joint bleeds, and annualized bleeding rate with preventive concizumab being investigated versus on-demand treatment across both HA and HB, with and without inhibitors. Summary of presentationsAccepted data at the 33rd ISTH Congress includes the following poster and oral presentations. Additional information can be found on the ISTH website. Full details of Novo Nordisk abstracts to be presented: Abstract title Abstract presentationdetails Hemophilia Investigational Mim8 FRONTIER5 direct switch study: Safety of initiating Mim8 prophylaxis without washout of emicizumab Oral presentation June 22 2:45-4:00 pm EST OC 20.4 Evaluating pen-injector handling and PROs in patients switching from emicizumab to Mim8 in FRONTIER5 Poster presentation June 23 1:45-2:45 pm EST PB0812 Mim8 enhances procoagulant activity of select hemophilia B-causing Factor IX variants (research collaboration) Oral presentation June 21 1:00-1:15 pm EST OC 03.1 Concizumab Non-joint bleeds in patients with hemophilia A or B with inhibitors: Concizumab explorer7 study Poster presentation June 23 1:45-2:45 pm EST PB0851 Annualized bleeding rates in hemophilia A/B and target joints: Concizumab explorer8 study Oral presentation June 24 2:45-4:00 pm EST OC 59.2 The effect of concizumab on thrombin generation in FVII deficient plasma Poster presentation June 24 1:45-2:45 pm EST PB1478 ISS study: TFPI slows prothombinase assembly when concizumab is bound to its second Kunitz domain Poster presentation June 24 1:45-2:45 pm EST PB1358 Taiwan study: Real-world efficacy of concizumab prophylaxis in a patient with hemophilia B and inhibitors Poster presentation June 23 1:45-2:45 pm EST PB0869 Pre-clinical data & general hemophilia In vitro activity of Inno8 in global hemostatic assays alone and with other hemostatic agents Oral presentation June 23 2:45-4:00 pm EST OC 39.5 Genomic integration of FVIII transgene in hepatocytes restores durable FVIII activity in vivo Oral presentation June 24 9:30-10:45 am EST OC 51.2 US physician-reported prophylactic treatment satisfaction and joint health of people with hemophilia Poster presentation June 24 1:45-2:45 pm EST PB1485 Joint bleed diagnosis and treatment delays in people with hemophilia: Global real-world data Poster presentation June 24 1:45-2:45 pm EST PB1423 About hemophiliaHemophilia is a rare inherited bleeding disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.2 It is estimated to affect approximately 1,125,000 people worldwide.3 There are different types of hemophilia, which are characterized by the type of clotting factor protein that is defective or missing. Hemophilia A is caused by a missing or defective clotting Factor VIII (FVIII), and hemophilia B is caused by a missing or defective clotting Factor IX (FIX).2 Hemophilia is often treated by replacing the missing clotting factor via intravenous infusions, also known as replacement therapy. However, sometimes the body can produce inhibitors as an immune response to the clotting factor replacement therapy. When this happens, the therapy may not work and can limit treatment options.5 About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a U.S. presence spanning 40 years, Novo Nordisk U.S. is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D, and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Østergaard H, Lund J, Greisen PJ, et al. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice. Blood. 2021;138(14):1258-1268. MedlinePlus. Hemophilia. Accessed May 2025. Available at Iorio A, Stonebraker JS, Chambost H, et al.; Data and demographics committee of the World Federation of Hemophilia. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546. Centers for Disease Control and Prevention (CDC). Treatment of hemophilia. Accessed May 2025. Available at Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25NNG00026 June 2025 View original content to download multimedia: SOURCE Novo Nordisk Sign in to access your portfolio
